36
Participants
Start Date
January 24, 2018
Primary Completion Date
July 31, 2025
Study Completion Date
November 30, 2025
CMV/AdV /EBV/BKV specific T cells
Each cohort of 2 patients will be treated and observed for 45 days for toxicity, dose escalation, and GvHD. The algorithm of sequentially adaptive EffTox trade-off-based design of Thall et al will be used to determine the dose for each cohort. If 1x107CTL/m2 results in unacceptable toxicity or efficacy, the study will be closed to accrual.
RECRUITING
Children's National Health System, Washington D.C.
RECRUITING
M.D. Anderson Cancer Center (MDACC), Houston
M.D. Anderson Cancer Center
OTHER
Catherine Bollard
OTHER